FMW Media's New to The Street TV, a nationally syndicated TV show,
announces episode #378, airing on the Fox Business Network tonight,
Monday, August 22, 2022, at 10:30 PM PT
New to The Street’s 378th
TV episode features the following five (5) Companies and their
representatives:
1). PetVivo Holdings, Inc.’s (NASDAQ: PETV)
(NASDAQ: PETVW) ($PETV) interview with John Lai, CEO &
President.
2). Mikra Cellular Sciences' (a division of
Lifeist Wellness, Inc.) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS:
NXTTF) interview with Faraaz Jamal, CEO.
3). "Unstoppable Women Entrepreneurs
Segment" – Integrity Payment Processing, Inc.'s interview
with Livia Caudell, CEO.
4). “Unstoppable Women Entrepreneurs
Segment” – Coastal Kapital, LLC’s interview with Kortney
Murray, CEO/Founder.
5). Tonix Pharmaceuticals, Inc.’s (NASDAQ:
TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO.
Episode #378
Tonight, New to The Street TV is
re-airing the Nasdaq Marketplace studio interview with John Lai,
CEO / President, PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV).
Talking with TV Host Jane King, John talks about PetVivo Holdings,
Inc., a biomedical device company that manufactures,
commercializes, and licenses innovative medical devices and
therapeutics for companion animals. John provides viewers his
corporate updates regarding PETV’s partnership with MWI Animal
Health, a leading animal health products and services distributor,
and Amerisource Bergen subsidiary. The relationship between PETV
and MWI Animal Health continues to mature, creating business
synergies. MWI Animal Health generates about $5B in revenues yearly
and has a seasoned sales and marketing staff. Their sales team now
markets PETV’s injectable patented Spryng with OsteoCushion
Technology that treats osteoarthritis and joint afflictions
for dogs, horses, and cats. A naturally derived product, Spryng
mimics collagen tissue that significantly improves animals’
afflicted joints. MWI’s success comes from educating their
veterinarian clients about their drug products, and now they are
rolling-out educational videos about Spryng. John says veterinarian
schools teach their doctors differently about treating animal
osteoarthritis. He feels confident that the videos and other
marketing materials can show Spryng successfully treating the
bone-on-bone root cause of the disease. Petvivocare.org is a
charitable organization at PETV which donates products to help
animal rescue organizations treat dogs, cats, horses, and other
animals suffering joint-related afflictions. Any animal care
organization can apply for assistance by providing reasons for
needing help. John is excited about business progress and looks
forward to returning to the show to share further updates. The
on-screen QR code is available during the show; download or visit
PetVivo Holdings, Inc. - https://petvivo.com/
and Spryng with OsteoCushion Technology -
https://www.sprynghealth.com/. The PETV interview originally aired
on August 15, 2022.
The interview with Faraaz Jamal, CEO at Mikra
Cellular Sciences ("Mikra"), a biosciences and consumer
wellness company that develops innovative therapies for cellular
health and a division of Lifeist Wellness, Inc. (TSXV: LFST
(FRANKFURT: M5B) (OTCMKTS: NXTTF) re-airs on tonight’s New to The
Street TV. Talking in-studio at the Nasdaq Marketplace, Jamal
explains to TV Host Jane King the Company's uniquely formulated
nutraceutical bio-active compounds. The CELLF™ product, once
ingested, absorbs the mineral/nutrient compounds through the small
intestines for cellular uses. Jamal reveals to viewers that
cellular health is the key to wellness and the link between
cellular activities and overall health. The vitamin market contains
misconceptions and false claims about overall consumer wellness.
Taking handfuls of pills is not the solution. Most of the time,
one's body does not need certain compounds but requires other
compounds. CELLF™ is a butter-type consistency that delivers its
nutrient-filled combinations directly to the jejunum (mid-small
intestine) and distributes from blood plasma to cells. The product
doesn't need individual customization; it absorbs compounds on the
cellular levels based on what the individual's body needs. Jamal
says that due to the human stress from COVID-19 and other social
and economic events, people are looking for ways to become healthy;
as such, the growth in wellness-based products continues. The
Company's recent consumer survey revealed that most people have
difficulty maintaining personal health. All the cells and organs of
the body are Mikra's targets to help individuals increase the
body's cellular ability to recover from any form of stress and
obtain a complete wellness solution. The parent Company, Lifeist
Wellness, Inc., is a business incubator in the health wellness
sector. It provides Mikra with the business and manufacturing
support necessary to produce its bioactive consumer products. The
on-screen QR code is available during the show; download or visit
Mikra Cellular Sciences - https://wearemikra.com/. The interview
originally aired on August 1, 2022.
Tonight, New to The Street TV re-airs the
"Unstoppable Women Entrepreneurs - Segment"
interview with Livia Caudell, CEO at Integrity Payment Processing,
Inc. ("Integrity"). In studio at the Nasdaq Marketplace, Livia
talks to TV Co-Hosts Jane King and Rhonda Swan about the Company's
business model. Integrity assists high-risk businesses like crypto,
nutraceuticals, CBD, cannabis, online gaming, and other industries
in getting them the best possible percentages when accepting credit
cards. Mostly these industries place payment tickets at more than
$2500; they are not your typical brick/mortar business. They need
unique solutions to ensure seamless transactions when accepting
debit/credit card payments. Livia is committed to assisting her
clients with the best possible solutions with the lowest possible
fees. Her most significant customers are in the cannabis industry,
where dispensaries need a safer alternative beyond cash. Taking
cards is a limited option for cannabis operators, and Integrity
Payment Processing offers them merchant services with several
merchant accounts. Many businesses who use Integrity's merchant
services see increases in their bottom lines from reduced cost and
sales increases from taking credit/debit cards as alternative
payment options beyond just cash. Without a merchant account, a
business cannot accept payments from a credit/debit card, and a
merchant account is a must in today's growing digital money
economy. Integrity Payments Processing, Inc. is a successful
woman-owned business helping businesses with merchant accounts. The
on-screen QR code is available during the show; download or visit
Integrity Payment Processing, Inc. -
https://www.integritypaymentprocessing.com/. The interview
originally aired on July 25, 2022.
The “Unstoppable Women Entrepreneurs -
Segment” interview with Kortney Murray, CEO/Founder of
Coastal Kapital, LLC, re-airs on tonight’s New to The Street. TV
Hosts Jane King and Rhonda Swan talk with Kortney in the studio at
the Nasdaq Marketplace about the Company’s commercial funding
operations. Kortney’s inspiration to start Coastal Kapital came
from her experience in two failed business ventures. The biggest
reason a company fails is a lack of capital or undercapitalization.
Entrepreneurs decide to leverage everything to make a go of their
businesses, and personal problems arise when things don’t go as
expected. Coastal Kapital is a non-bank and non-credit report
funding source focusing on asset-based lending, working capital
needs, equipment leasing, business loans, merchant processing, and
real-estate-backed funding. Kortney explains that Coastal Kapital
looks at the individual and decides on needs based on the business
model and a client’s aggressive posture and efforts. She helps
other women find equipment solutions and other capital sources for
the needs of their businesses and mentors and educates women on
other business principles to help ensure success. Coastal Kapital,
in the future, would like to open avenues for capital creation and
assistance for women outside of the US, fund those entities, and
provide business help accordingly. Kortney’s story is a chapter in
the book by the TV Co-host Rhonda Swan: “Women Gone Wild: The
Feminine Guide To Fearless Living.” The on-screen QR code is
available during the show; download or visit Coastal Kapital, LLC -
https://coastalkapital.com/. The interview originally aired on July
25, 2022.
New to The Street TV, tonight, re-airs TV Host
Jane King’s interview with Dr. Seth Lederman, MD, CEO at Tonix
Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP), a clinical-stage
biopharmaceutical Company. Talking from the Nasdaq Marketplace
studio, Seth updates viewers about the Company’s current
operations. Monkeypox is a global problem with over 17,000 cases
outside of Africa, and Seth believes that the infection rate
doubles each week. The WHO (World Health Organization) recently
declared Monkeypox an international health emergency. For about ten
years, Tonix Pharmaceuticals continue with the clinical development
of the TNX-801 live vaccine to prevent Monkeypox and Smallpox. The
overwhelming majority of those affected are men who have sex with
men (“MSM”). Since Monkeypox is NOT an STD (sexually transmitted
disease), other population demographics could catch the virus. Seth
informs viewers about the Company’s live virus vaccine they are
developing to prevent COVID. Unfortunately, current vaccines are
not protective enough and have limited durations. Tonix intends to
have its COVID vaccine overcome the current marketplace vaccine
limitations. The Company opened its new “Advanced Development
Center” that will manufacture clinical trial supplies for live
virus vaccines for both COVID and Monkeypox. Even with economic
short-coming caused by COVID displacement, TNXP opened the new
manufacturing center in about 1-year. The facility can respond to
President Biden’s “American Pandemic Preparedness Plan” (AP3), so
Tonix can make, in 100-days, new vaccines to prevent new pathogen
infections. Tonix is committed to improving the lives of patients
by identifying, researching, and developing promising therapies
which have the potential to address unmet needs. Dr. Lederman will
come back on a future show with further updates. The on-screen QR
code is available during the show; download or visit Tonix
Pharmaceuticals, Inc. - https://www.tonixpharma.com/. The TNXP
interview originally aired on August 15, 2022.
About PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ:
PETVW) ($PETV):
PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ:
PETVW) ($PETV) is an emerging biomedical device company focused on
manufacturing, commercializing, and licensing innovative medical
devices and therapeutics for companion animals. The Company’s
strategy is to leverage human therapies for treating companion
animals cost-effectively and time-efficiently. A vital component of
this strategy is the accelerated timeline to revenues for
veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for treating animals
and people. A portfolio of nineteen patents protects the Company’s
biomaterials, products, production processes, and methods of use.
The Company’s lead product SPRYNG™ with
OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint-related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale -
https://petvivo.com/.
About Mikra Cellular
Sciences:
Mikra Cellular Sciences ("Mikra"), a division of
Lifeist Wellness, Inc. (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS:
NXTTF), is a breakthrough Company seeking to unlock cellular
potential and maximize the health of humans. Mikra intends to
bridge the scientific gap between cellular health and consumer
wellness and focuses on one's health at the cellular level.
Human cells are responsible for the overall functionality of human
biology. Mikra continues to develop products that can enhance
cellular absorption of key and need minerals and nutrients to
improve health and wellness. CELLF™ product is clinically tested
and engineered to bring balance to the body and mind on a cellular
level -https://wearemikra.com/. Lifeist Wellness, Inc. (TSXV: LFST)
(FRANKFURT: M5B) (OTCMKTS: NXTTF) is sitting at the forefront of a
post-pandemic wellness revolution, leveraging the advancements in
science and technology to build breakthrough companies that
transform human wellness. Its portfolio business units include
CannMart, a B2B wholesale distribution business that facilitates
recreational cannabis sales to Canadian provincial government
control boards; CannMart Labs, a BHO extraction facility for the
production of high-margin cannabis 2.0 products;
the CannMart.com marketplace, which provides US customers
with access to hemp-derived CBD and smoking accessories; Australian
Vapes, the country's largest online retailer of vaporizers and
accessories; Findify, a leading AI-powered search and discovery
platform; and Mikra, a biosciences and consumer wellness company
seeking to develop innovative therapies for cellular health.
Information on Lifeist and its businesses - www.lifeist.com,
www.cannmart.com, www.australianvaporizers.com.au,
www.wearemikra.com, and email: ir@lifeist.com.
About Integrity Payment
Processing, Inc.:
Integrity Payment Processing, Inc. offers the
lowest rates and has 5-star customer service with 100% transparency
in prices/fees, no application fees, and no integration fees. They
understand that each customer has a unique business and that a
standard merchant account is inadequate for their business
operations. The electronic payment industry is not a
one-solution-fits-all industry. Integrity Payment Processing, Inc.
works hard to understand its clients' unique payment processing
needs and customizes the best solutions for growth. Integrity
Payment Processing is the premier payment solutions company that
excels in tailoring solutions to the cannabis industry -
https://www.integritypaymentprocessing.com/.
About Coastal Kapital,
LLC.
Coastal Kapital, LLC provides businesses with the
capital needed to get a competitive edge, maximizing a company’s
profits. Helping companies succeed since 2007, Coastal Kapital
account executives with over 14 years of experience have
relationships with over 150 different programs. Their clients
understand that time equals money, and Coastal Kapital is the
one-stop shop for all your financial needs and offers its clients
the most innovative programs. They offer equipment leasing,
business loans, working capital, merchant Processing, collateral
asset, and real estate-backed funding, regardless of credit type.
Coastal Kapital is a dedicated financial service leader in
commercial equipment and asset-based lending and maintains
relationships with business owners, vendors, and manufacturers
across the US who value partnerships well as Integrity -
https://coastalkapital.com/.
About Tonix Pharmaceuticals Holding Corp.
(NASDAQ: TNXP) ($TNXP):
Tonix Pharmaceuticals Holding Corp. (NASDAQ:
TNXP) ($TNXP) is a clinical-stage biopharmaceutical company focused
on discovering, licensing, acquiring, and developing small
molecules and biologics to treat and prevent human disease and
alleviate suffering. Tonix’s portfolio comprises immunology, rare
disease, infectious disease, and central nervous system (CNS)
product candidates. Tonix’s immunology portfolio includes biologics
to address organ transplant rejection, autoimmunity, and cancer.
TNX-15001 is a humanized monoclonal antibody targeting CD40-ligand
in development to prevent allograft and xenograft rejection and
treat autoimmune diseases. A Phase 1 study of TNX-1500 is expected
to be initiated in the second half of 2022. Tonix’s rare disease
portfolio includes TNX-29002 for the treatment of Prader-Willi
syndrome. The FDA has granted TNX-2900 Orphan-Drug Designation.
Tonix’s infectious disease pipeline consists of a vaccine in
development to prevent smallpox and Monkeypox called TNX-8013,
next-generation vaccines to prevent COVID-19, and an antiviral to
treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are
TNX-1840 and TNX-18504, live virus vaccines based on Tonix’s
recombinant pox vaccine (RPV) platform. TNX-35005
(sangivamycin, i.v. solution) is a small molecule
antiviral drug to treat acute COVID-19 and is in the pre-IND stage
of development. TNX-102 SL, (cyclobenzaprine HCl sublingual
tablets) is a small molecule drug developed to treat Long COVID, a
chronic post-acute COVID-19 condition. Tonix expects to initiate a
Phase 2 study in Long COVID in the second quarter of 2022. The
Company’s CNS portfolio includes small molecules and biologics to
treat pain, neurologic, psychiatric, and addiction conditions.
Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3
development to manage fibromyalgia, with a new Phase 3 study
launched in the second quarter of 2022. Finally, TNX-13006 is a
biologic designed to treat cocaine intoxication, expects to start a
Phase 2 trial in the second quarter of 2022
- https://www.tonixpharma.com. (1TNX-1500 is an
investigational new biologic at the pre-IND stage of development
and has not been approved for any indication.2TNX-2900 is an
investigational new drug at the pre-IND stage of development and
has not been approved for any indication.3TNX-801 is a live
horsepox virus vaccine for percutaneous administration in
development to protect against smallpox and Monkeypox. TNX-801 is
an investigational new biologic and has not been approved for any
indication.4TNX-1840 and TNX-1850 are live horsepox virus vaccines
for percutaneous administration, in development to protect against
COVID-19. TNX-1840 and TNX-1850 are designed to express the
SARS-CoV-2 spike protein from the omicron and BA.2 variants,
respectively. TNX-1840 and TNX-1850 are investigational new
biologics at the pre-IND stage of development and have not been
approved for any indication. 5TNX-3500 is an investigational new
drug at the pre-IND stage of development and has not been approved
for any indication.6TNX-1300 is an investigational new biologic and
has not been approved for any indication.)
About FMW Media:
FMW Media operates one of the longest-running US
and International sponsored and Syndicated Nielsen Rated
programming TV brands, “New to The Street” and its blockchain show
“Exploring The Block.” Since 2009, these brands have run
biographical interview segment shows across major U.S. Television
networks. The paid-for-TV programming platforms can potentially
reach over 540 million homes in the US and international markets.
FMW’s New to The Street / Newsmax TV broadcasting platform airs its
syndication on Sundays at 10 -11 AM ET. FMW is also one of the
nation’s largest buyers of linear television, long and short-form
paid programming
- https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would,” or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. This press release should be considered in all filings of
the Companies contained in the Edgar Archives of the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
FMW Media Contacts:
Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
“New to The Street” Business Development Office
1-516-696-5900 Support@NewtoTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/331f11d1-940e-4f70-80d7-084c8364591f
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Mar 2024 to Apr 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Apr 2023 to Apr 2024